Skip to main content
. 2021 Jul 3;23(8):1516–1525. doi: 10.1111/jch.14314

TABLE 2.

Hazard ratio of SBP variability for all‐cause mortality (four BP measurements)

Overall (n = 7996) Standard therapy (n = 3995) Intensive therapy (n = 4001)
Model 1 Model 2 Model 1 Model 2 Model 1 Model 2
SBP VIM
Continuous
+5.6 U 1.21(1.08‐1.36)*** 1.18(1.05‐1.32)** 1.25(1.08‐1.43)** 1.19(1.04‐1.36)* 1.15(0.95‐1.41) 1.15(0.94‐1.40)
Quintiles
Q1 Reference Reference Reference Reference Reference Reference
Q2 1.24(0.77‐1.98) 1.20(0.75‐1.92) 1.51(0.81‐2.81) 1.45(0.78‐2.71) 0.94(0.45‐1.95) 0.91(0.44‐1.90)
Q3 1.60(1.03‐2.49)* 1.53(0.98‐2.39) 1.74(0.95‐3.16) 1.65(0.91‐3.01) 1.45(0.75‐2.81) 1.42(0.73‐2.76)
Q4 1.48(0.95‐2.31) 1.40(0.90‐2.20) 1.39(0.76‐2.57) 1.32(0.72‐2.44) 1.64(0.85‐3.16) 1.57(0.81‐3.03)
Q5 1.87(1.22‐2.87)** 1.71(1.11‐2.63)* 2.08(1.18‐3.66)* 1.85(1.05‐3.26)* 1.60(0.67‐4.62) 1.54(0.79‐3.02)
SBP MMD
Continuous
+13.1 mmHg 1.26(1.14‐1.40)*** 1.21(1.09‐1.35)*** 1.23(1.07‐1.40)** 1.17(1.01‐1.35)* 1.31(1.12‐1.55)*** 1.30(1.09‐1.53)**
Quintiles
Q1 Reference Reference Reference Reference Reference Reference
Q2 1.32(0.78‐2.23) 1.27(0.75‐2.16) 1.30(0.66‐2.55) 1.25(0.63‐2.46) 1.36(0.59‐3.13) 1.31(0.57‐3.03)
Q3 1.72(1.04‐2.84)* 1.63(0.99‐2.71) 1.74(0.92‐3.30) 1.66(0.87‐3.14) 1.66(0.73‐3.75) 1.60(0.70‐3.63)
Q4 1.99(1.23‐3.21)** 1.86(1.15‐3.00)* 1.73(0.93‐3.21) 1.61(0.87‐2.98) 2.47(1.16‐5.27)* 2.34(1.09‐5.02)*
Q5 2.28(1.42‐3.67)*** 2.04(1.26‐3.30)** 1.92(1.04‐3.53)* 1.66(0.90‐3.08) 3.00(1.41‐6.37)** 2.84(1.32‐6.08)**

Model 1 with adjustment of randomized group and FRS stratification.

Model 2 further adjusted with history of CKD, fasting glucose, mean number of antihypertensive agents, and statin and aspirin use.

Abbreviations: MMD, the difference of maximum minus minimum; Q1‐5, quintile 1–5; SBP, systolic blood pressure; VIM, variability independent of the mean.

*p < .05; **p < .01; ***p < .001.